Mitochondrial complex II, also known as succinate dehydrogenase, is well-known for its dual role in the tricarboxylic acid (TCA) cycle and the electron transport chain, making it essential for energy production in cells. In AML, researchers have discerned that blockage of complex II leads to a significant build-up of critical metabolites including succinate, alpha-ketoglutarate (α-KG), and glutamate, with profound downstream effects on amino acid pathways. The intricate metabolic crosstalk exposed by these findings sheds light on how leukemic cells heavily rely on functional complex II to maintain their proliferative and survival advantages.

To probe the biological impact of metabolite accumulation, the research team utilized cell-permeable dimethyl esters: dimethyl-succinate (DMS), dimethyl-alpha-KG (DMKG), and dimethyl-glutamate (DMG). Remarkably, glutamate accumulation, simulated by DMG treatment, exhibited a cytotoxic effect tenfold more potent than DMS or DMKG across AML cells harboring diverse genetic mutations such as KMT2A, FLT3, NRAS, and TP53. This striking sensitivity to DMG underscores glutamate’s pivotal role as a metabolic node that, when dysregulated, can collapse leukemic cell viability.

Delving deeper, the study revealed that AML cells react to complex II inhibition by rerouting metabolic fluxes. Glutamate produced during purine biosynthesis, wherein glutamine donates nitrogen to key intermediates, normally supports the TCA cycle via anaplerosis—refilling cycle intermediates that sustain energy and biosynthetic processes. However, upon complex II blockade, glutamate fails to effectively enter the TCA cycle, leading to its intracellular accumulation. This accumulation not only inhibits purine synthesis but also entails glutamate export through system Xc− and incorporation into glutathione biosynthesis, processes intimately linked to redox homeostasis.

The ramifications of glutamate accumulation were strikingly confirmed by metabolic assays showing that three distinct complex II inhibitors increased intracellular glutamate levels in AML lines. Interestingly, the addition of exogenous glutamate heightened cell sensitivity to complex II inhibition, suggesting that glutamate overload exacerbates metabolic stress and compromises leukemia cell fitness. This interrelationship between glutamate handling and complex II function reveals a metabolic bottleneck exploitable for therapeutic intervention.

A significant insight from this research is the inability of glutamate to compensate for glutamine withdrawal in AML. Normally, glutamine-derived carbons replenish the TCA cycle, but the study’s results highlight that dimethyl-succinate and dimethyl-alpha-KG can rescue AML cell growth under low-glutamine conditions, unlike dimethyl-glutamate. This differential effect cements the concept that glutamine metabolism in AML depends heavily on downstream metabolites that feed the TCA cycle rather than glutamate per se, which may have toxic secondary effects when accumulated.

The role of glutamate in regulating redox balance emerged as a crucial adaptive pathway in the face of complex II inhibition. Glutamate is a precursor for glutathione synthesis and modulates cystine import via system Xc−, critical for maintaining antioxidant defenses. The research demonstrated that complex II blockade induced significant changes in glutathione metabolism, pushing AML cells to channel glutamate toward glutathione production. Inhibition of system Xc− with erastin further elevated intracellular glutamate and diminished cell viability synergistically with complex II inhibitors, illustrating the therapeutic potential of co-targeting glutamate metabolism.

Metabolomic profiling unveiled that glutamate accumulation following DMG treatment profoundly suppresses purine nucleotide pools, including key intermediates such as 5-amino-4-imidazolecarboxamide ribonucleotide (AICAR), adenylosuccinate, ADP, and ATP. By downregulating purine biosynthesis, glutamate accumulation undermines nucleotide availability essential for DNA and RNA synthesis, thereby hampering AML cell proliferation and survival. This mechanistic understanding elucidates how complex II functions not only as a metabolic enzyme but also as an indirect regulator of nucleotide biosynthesis essential for leukemia maintenance.

The discovery of this metabolic chokepoint offers a promising new avenue for AML therapy. Targeting complex II to induce glutamate accumulation, possibly in combination with agents that limit glutamate export or glutathione biosynthesis, could synergistically amplify metabolic stress and selectivity against leukemic cells. This strategy exploits a fundamental biochemical dependency of AML cells on complex II integrity and glutamate homeostasis, representing a precision medicine approach grounded in metabolic reprogramming.

Notably, the study underscores that AML’s metabolic wiring differs markedly from normal hematopoietic cells, which may explain the unique susceptibility of leukemia to complex II inhibition and glutamate toxicity. By pinpointing glutamate as a key mediator of purine biosynthesis inhibition, this research challenges the traditional perspective that mitochondrial defects simply reduce energy generation, instead emphasizing their nuanced role in shaping nucleotide metabolism and redox balance in cancer.

Importantly, the implication that glutamate accumulation acts as a metabolic stress signal, suppressing purine synthesis, situates this metabolite as more than a passive substrate but as an active regulator of cellular biosynthetic capacity. This insight prompts reconsideration of metabolic intermediates as dynamic regulators in cancer biology with roles extending beyond their canonical biochemical functions.

The elucidation of this pathway also raises intriguing questions about the broader applicability of complex II targeting beyond AML. Given that many cancers display altered mitochondrial metabolism and nucleotide synthesis demands, the mechanism described may represent a generalized vulnerability. However, the specificity seen in AML suggests that genetic and metabolic context dictate responses to complex II inhibition and glutamate-induced stress.

Furthermore, the study’s methodological approach, harnessing pathway coessentiality mapping combined with isotope tracing and metabolic assays, establishes a robust framework for unraveling complex biochemical networks in cancer. This multifaceted strategy provides comprehensive insights linking enzyme function, metabolite fluxes, and cellular phenotypes, advancing our understanding of metabolic dependencies in malignancy.

Overall, this research shifts the paradigm in leukemia metabolism by revealing a critical dependency on complex II for maintaining purine biosynthesis via glutamate regulation. The findings spotlight new metabolic checkpoints amenable to therapeutic intervention and propose combinatorial strategies that enhance glutamate-induced cytotoxicity alongside mitochondrial inhibition. As such, this study paves the way for innovative metabolic therapies combatting AML with unprecedented precision and efficacy.

In conclusion, the identification of glutamate accumulation as a metabolic liability in AML upon complex II inhibition represents a major stride in cancer metabolism research. This work not only elucidates novel biochemical pathways underpinning leukemia survival but also inspires new therapeutic directions that exploit metabolic vulnerabilities to eradicate malignant cells. The promise of targeting these intertwined metabolic axes holds significant potential to improve outcomes for patients afflicted with this aggressive hematologic cancer.

Subject of Research:
Acute myeloid leukemia (AML) metabolism; role of mitochondrial complex II in purine biosynthesis and glutamate accumulation.

Article Title:
Pathway coessentiality mapping reveals complex II is required for de novo purine biosynthesis in acute myeloid leukaemia.

Article References:
Stewart, A.E., Zachman, D.K., Castellano-Escuder, P. et al. Pathway coessentiality mapping reveals complex II is required for de novo purine biosynthesis in acute myeloid leukaemia. Nat Metab (2025). https://doi.org/10.1038/s42255-025-01410-x

Image Credits:
AI Generated

DOI:
https://doi.org/10.1038/s42255-025-01410-x

Acute myeloid leukemia is notorious for its rapid progression and resistance to conventional therapies, often leading to poor clinical outcomes and high mortality rates. At the heart of AML’s malignancy lies a complex network of genetic and epigenetic alterations, among which aberrant activation of oncogenes like MYC is a recurring theme. MYC orchestrates an array of cellular processes essential for cancer cell survival, including metabolism, cell cycle progression, and apoptosis evasion. However, targeting MYC directly has remained an elusive goal due to its “undruggable” nature, leaving scientists to explore upstream regulatory mechanisms that govern its function.

The recent study spearheaded by Zhao, K., Zhang, H., Wang, S., and colleagues breaks new ground by identifying METTL13 as a critical post-transcriptional modulator of MYC in AML cells. METTL13, a member of the methyltransferase family, enzymatically modifies specific substrates through methylation, thereby altering their function and stability. Through an intricate series of in vitro and in vivo experiments, the researchers demonstrated that silencing METTL13 expression led to a marked decrease in MYC levels, which in turn severely compromised leukemia cell viability. This direct link illuminated a previously uncharted regulatory layer influencing MYC activity and AML cell survival.

Delving deeper into molecular details, the study elucidated how METTL13-mediated methylation impacts the translation machinery and protein synthesis within AML cells. METTL13 was found to methylate components involved in the initiation of mRNA translation, thereby enhancing the production of MYC protein. This post-transcriptional control mechanism allows leukemia cells to sustain high MYC protein levels irrespective of changes in MYC mRNA expression, highlighting a sophisticated strategy that leukemia cells exploit to maintain their oncogenic drive. Such insights deepen our understanding of cancer biology, particularly showcasing how epigenetic modifications intersect with gene expression regulation to fuel malignancy.

To validate the clinical relevance of their findings, the researchers analyzed patient-derived AML samples and corroborated that METTL13 expression was significantly elevated compared to healthy controls. This overexpression correlated with higher MYC protein levels, reinforcing the pathophysiological link described in experimental models. Furthermore, patients exhibiting increased METTL13 activity had poorer prognostic indicators, suggesting METTL13 could serve as both a biomarker and a therapeutic target in AML. These correlations underscore the translational potential of targeting METTL13 to disrupt MYC-driven leukemogenesis.

Crucially, functional assays revealed that pharmacological inhibition or genetic knockdown of METTL13 induced apoptosis in AML cell lines without affecting normal hematopoietic cells, hinting at a therapeutic window that could be exploited for selective AML targeting. This specificity offers hope for designing treatments that minimize collateral damage to healthy tissue, a fundamental challenge in current chemotherapy regimens. The study also provided preliminary evidence that combining METTL13 inhibition with existing therapies could potentiate anti-leukemic effects, laying a foundation for combinatorial treatment strategies.

The mechanistic insights uncovered by Zhao and colleagues have broad implications, especially considering the notorious difficulty of directly targeting MYC. By shifting the therapeutic focus upstream to METTL13, researchers are unveiling a novel strategy that could circumvent previous barriers. Moreover, understanding how methyltransferase enzymes modulate oncogene expression opens new investigative pathways in cancer biology, as similar mechanisms may be operative in other malignancies characterized by MYC dysregulation.

From a therapeutic development perspective, the discovery that METTL13 supports leukemia cell survival via MYC regulation ignites enthusiasm for drug discovery efforts aimed at inhibiting this enzyme’s methyltransferase activity. Small-molecule inhibitors targeting METTL13 could represent the next generation of epigenetic therapies, with the potential for high efficacy and reduced systemic toxicity. Nonetheless, challenges remain, including the need to delineate METTL13’s role in normal physiology to avoid unintended side effects, and optimizing inhibitor specificity to prevent off-target interactions.

The study further sheds light on the broader landscape of epitranscriptomics—the diverse chemical modifications that regulate RNA function and protein synthesis. METTL13’s influence on mRNA translation through methylation exemplifies how post-transcriptional modifications profoundly impact cellular behavior and cancer biology. As investigations into the epitranscriptomic code accelerate, enzymes like METTL13 may emerge as central nodes controlling oncogenic programs across cancer types.

Beyond AML, these findings encourage a reevaluation of methyltransferase enzymes’ roles across hematological and solid tumors. Given MYC’s ubiquitous involvement in many cancers, targeting METTL13 or similar modifiers could herald new therapeutic directions with wide applicability. Additionally, the ability to disrupt cancer cell survival pathways at the translational level represents a paradigm shift, signifying an era where cancer treatment is informed by multilayered regulatory networks rather than single-gene targets.

In the clinical context, integrating METTL13 expression levels into diagnostic and prognostic workflows could refine patient stratification and guide personalized treatment decisions. Patients with elevated METTL13 might benefit from tailored therapies that specifically disrupt the METTL13-MYC axis. Moreover, monitoring METTL13 activity longitudinally could serve as an indicator of treatment response and disease progression, aiding clinicians in optimizing management strategies.

The discovery also emphasizes the importance of interdisciplinary research, combining molecular biology, biochemistry, genomics, and clinical sciences to unravel complex oncogenic pathways. The collaborative approach enabled a comprehensive characterization of METTL13’s function from molecular mechanisms to clinical implications, serving as a model for future translational cancer research endeavors.

Looking ahead, the field is poised for exciting developments as efforts focus on designing and testing METTL13 inhibitors in preclinical models and eventually clinical trials. Success in these steps could revolutionize AML therapy, offering hope for improved survival and quality of life for patients afflicted by this aggressive leukemia. The ongoing work will also likely stimulate broader investigations into epigenetic regulation mechanisms underpinning cancer, potentially unveiling new classes of druggable targets.

In conclusion, the revelation that METTL13 is indispensable for AML cell survival by modulating MYC expression not only enriches the understanding of leukemia biology but also spotlights a promising therapeutic target with far-reaching implications. By bridging epitranscriptomics and oncogenic signaling, this study paves the way for innovative cancer treatments that disrupt fundamental pathological processes. As research progresses, targeting METTL13 may emerge as a game-changer in the fight against AML and beyond, offering renewed optimism in conquering one of the deadliest forms of cancer.

Subject of Research: The role of METTL13 in the survival of acute myeloid leukemia cells through regulation of MYC.

Article Title: METTL13 is essential for the survival of acute myeloid leukemia cells by regulating MYC.

Article References:
Zhao, K., Zhang, H., Wang, S. et al. METTL13 is essential for the survival of acute myeloid leukemia cells by regulating MYC. Cell Death Discov. 11, 240 (2025). https://doi.org/10.1038/s41420-025-02512-x

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41420-025-02512-x